Aktuellt
SENASTE
Bactiguard’s Q1 sales of SEK 41.8m were in line with our expectations. Q1 adj. EBITDA amounted to SEK 1.9m (SEB at SEK -1.2m). Bactiguard comments that it saw a continued recovery in the licensing business with BD and positive development for its BIP portfolio in the quarter, however, that sales of BIP products is still affected by reduced general healthcare. After a first glance of the report, we expect only minor revisions to estimates post Q1 (prel.).
LÄS MER
